Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
NCT ID NCT07490275
First seen Mar 25, 2026 · Last updated Apr 25, 2026 · Updated 4 times
Summary
This early-phase trial tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard therapies. The treatment uses donor immune cells (γδT cells) that are engineered to target and attack faulty B cells. The main goal is to check safety and find the right dose in a small group of 9 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY/RELAPSED SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.